RxDoctor Payments Data

Sagar Desai, MD

Internal Medicine · Edison, NJNPI 1386649861

Payments from drug & device makers

$11,793in general payments, 2019–2025

Across 532 payments — averaging $22.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$1K
  • Bayer$802
  • Penumbra, Inc.$796
  • Lilly USA, LLC$712
  • AbbVie$699
  • plus $6K from 36 others

What the payments were for

  • Travel & lodging$5765%
  • Food & beverage$11,20395%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,793 in reported general payments places this provider in the 90th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$587,036
Medicare patients
548
Services billed
4,755

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin115$102,816
EliquisApixaban147$99,826
JanuviaSitagliptin Phosphate118$60,587
OzempicSemaglutide35$49,805
JanumetSitagliptin Phos/Metformin Hcl40$34,906
LinzessLinaclotide45$34,876
XareltoRivaroxaban39$29,979
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$27,186
TradjentaLinagliptin47$22,067
FarxigaDapagliflozin Propanediol24$17,995
Breo ElliptaFluticasone/Vilanterol32$15,425
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$12,420
JentaduetoLinagliptin/Metformin Hcl12$11,727
LokelmaSodium Zirconium Cyclosilicate16$8,694
RestasisCyclosporine16$7,866

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Jentadueto$670$136,610174 claims
PfizerEliquis, Retacrit$128$102,718158 claims
MerckJanuvia, Janumet$92$95,493158 claims
Novo NordiskOzempic, Fiasp$1,715$54,80651 claims
AbbVieLinzess, Restasis, Synthroid$699$45,23196 claims
GSKTrelegy Ellipta, Breo Ellipta$411$42,61154 claims
Johnson & JohnsonXarelto, Procrit$401$33,02652 claims
AstraZenecaFarxiga, Lokelma$1,489$26,68840 claims
NovartisEntresto$223$5,08415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Edison

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →